Drugs / AG011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00729872 | Jul 2008 → Sep 2009 | ulcerative colitis | ActoGeniX N.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00729872 ↗ |
| Modality | Other / unclassified | “AG011 is the clinical formulation of a genetically modified L. lactis that has been engineered to secrete human Interleukin-10 (hIL-10).” NCT00729872 ↗ |
| Route | Rectal | “Study medication will be provided in capsule and enema (topical rectal application) forms by ActoGeniX NV.” NCT00729872 ↗ |